Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) …
Patients Taking AUSTEDO XR® (deutetrabenazine)
Sep 21, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis …
AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors.
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® …
Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia …
May 30, 2024 · The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
Dosing for Tardive Dyskinesia | AUSTEDO XR® (deutetrabenazine)
Learn about once-daily dosages for AUSTEDO XR® (deutetrabenazine) extended release tablets for Tardive Dyskinesia (TD). See safety info and Boxed Warning.
FDA approves new doses of Austedo XR for tardive dyskinesia
Jun 3, 2024 · The FDA has approved Austedo XR in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with Huntington’s disease, according …
Teva Announces FDA Approval of AUSTEDO® XR ... - Teva …
Feb 17, 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis …